Stay updated on Pembrolizumab in HER2+ Gastric Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HER2+ Gastric Clinical Trial page.

Latest updates to the Pembrolizumab in HER2+ Gastric Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check20 days agoChange DetectedThe page has been updated to include new drug identifiers and a revision number, while significant details about the study's design and treatment protocols have been removed.SummaryDifference15%
- Check27 days agoChange DetectedThe date has been updated from March 25, 2025, to March 17, 2025.SummaryDifference0.1%
- Check35 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check42 days agoChange DetectedThe page has been updated to reflect a new revision version (v2.14.3) and a new date for the results first posted, changing from March 17, 2025, to March 25, 2025.SummaryDifference0.1%
- Check49 days agoChange DetectedThe webpage has been updated to reflect new results and criteria for a clinical study involving pembrolizumab and trastuzumab for HER2 positive gastric cancer, with specific details on treatment protocols and efficacy measures. The results reporting dates have also been updated.SummaryDifference14%
Stay in the know with updates to Pembrolizumab in HER2+ Gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HER2+ Gastric Clinical Trial page.